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Abstract

Background: Extended-Spectrum β-Lactamase (ESBL) producing Enterobacteriaceae have become widespread in hospitals and
are increasing in community settings where they cause a variety of infections. In addition to hydrolyzing most beta-lactam agents,
bacteria harboring these enzymes display resistance to other unrelated antimicrobial agents and thus often pose a therapeutic
dilemma. Though these resistance patterns have been studied elsewhere within Africa, such data from hospitals in Kenya are
scanty. We therefore undertook to determine these patterns at the Aga Khan University hospital by studying multidrug resistant
Escherichia coli and Klebsiella pneumoniae isolates from patients’ samples.
Findings: A total of 159 isolates (109 E. coli and 50 K. pneumoniae) were confirmed as ESBL producers and tested against
eighteen antimicrobials. The proportion of resistant isolates was high (>80%) for the antimicrobials tested with the exception of
the carbapenems (<1%), nitrofurantoin (23%) and gentamicin (63%). Klebsiella pneumoniae had a higher proportion of isolates
resistant to ceftazidime, gentamicin and nitrofurantoin (P < 0.05) than E. coli which had a higher proportion of isolates resistant to
ciprofloxacin, levofloxacin and tetracycline (P < 0.05).
Conclusions: In our study, antimicrobial coresistance is common in ESBL producers; however resistance to carbapenems is low
and these drugs would be the appropriate empiric therapy for serious or life threatening systemic infections. Nitrofurantoin retains
good activity among the multidrug resistant isolates and can be the drug of choice for non-complicated urinary tract infections
due to ESBL producing E. coli.
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Background

The precise definition of the term Extended-Spectrum
β-Lactamase (ESBL) remains unclear but is generally used
to refer to any β-lactamase, ‘generally acquired rather than
inherent to a species, that is either able to confer resistance
to oxyimino-cephalosporins (but not carbapenems), or that
has an increased ability to do so, as compared with classic
members of its genetic family’ [1].
ESBL producing strains of Enterobacteriaceae have emerged
as a major problem in hospitalized as well as community based
patients [2]. These organisms are responsible for a variety of
infections like urinary tract infection (UTI), septicemia, hospital
acquired pneumonia, intra-abdominal abscess, brain abscess
and device related infections.
Organisms producing ESBLs are clinically relevant and remain
an important cause of failure of therapy with cephalosporins
[3]. ESBLs are primarily produced by the Enterobacteriaceae
family, in particular Klebsiella pneumoniae and Escherichia coli [4].
Bacteria harboring ESBLs may also acquire and most often
exhibit additional resistances to other antimicrobial classes such
as the quinolones, tetracyclines, cotrimoxazole, trimethoprim,
and aminoglycosides, which further limits therapeutic options

and thus pose a therapeutic dilemma [5-8].
The Aga Khan University hospital (AKUH) is a private tertiary
institution located in Nairobi, Kenya, with twenty satellite clinics
spread across the country that send specimens for culture to
the main laboratory. Among the Enterobacteriaceae, E. coli
and K. pneumoniae are the two most isolated organisms from
patients’ samples in the hospital’s microbiology section and
ESBL producing isolates account for approximately 8% of the
two species. Cephalosporins are among the most prescribed
antibiotics in the hospital. In the year 2009 about 250,000 doses
of ceftriaxone were consumed in the outpatient department
alone. The antibiotic susceptibility profiles of these ESBL
producing isolates have not been previously described in this
hospital and are the focus of this study.

Methods

Three hundred thirty six multidrug resistant isolates cultured
from clinical specimens and which were reported as E. coli
and K. pneumoniae by use of routine bench biochemical tests
and stored at -800C in a broth medium with glycerol during
the period 2007 to 2009 were included in the study. Only one
isolate per patient was included. The isolates were revived on
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Table1. Distribution of clinical specimens and isolates cultured.
Inpatient
Specimen type

Outpatient

E. coli K. pneumoniae E. coli K. pneumoniae Total

ABDOMINAL DRAIN

1

0

0

0

1

ASITIC FLUID

1

0

0

0

1

AXILLA SWAB

2

0

0

0

2

BRONCHIAL LAVAGE
FLUID

0

1

0

0

1

BLOOD

1

1

0

0

2

CATHETER TIP

0

1

0

0

1

CSF

1

0

0

0

1

ENDOCERVICAL SWAB

0

0

1

0

1

GROIN SWAB

1

0

0

0

1

JOINT ASPIRATE

0

1

0

0

1

NASAL SWAB

0

1

0

0

1

PUS SWAB

5

8

6

2

21

SPUTUM

2

3

0

1

6

TRACHEAL ASPIRATE

1

3

0

0

4

URINE

23

15

64

13

115

Total

38

34

71

16

159

Table2. Antibiotic susceptibilities of the isolates n=159.
Antibiotic

Resistant

Sensitive

No (%)

No (%)

Amoxicillin/Clavulanate

159 (100%)

0

Ampicillin

159 (100%)

0

Ceftazidime

144 (90.6%)

15 (9.4%)

Cefuroxime

158 (99.4%)

1(0.6%)

132 (83%)

27 (17%)

158 (99.4)

1 (0.6%)

Ciprofloxacin
Cefpodoxime
Cefotaxime

158 (99.4%)

1 (0.6%)

Gentamicin

101 (63.6%)

58 (36.4%)

Imipenem

1 (0.6%)

158 (99.4%)

Levofloxacin

128 (80.5%)

31 (19.5%)

Meropenem

1 (0.6%)

158 (99.4%)

Nitrofurantoin

37 (23.3%)

122 (76.7%)

Piperacillin

159 (100%)

0

Roxithromycin

159 (100%)

0

Sulfamethoxazole/Trimethoprime

144 (90.6%)

15 (9.4%)

Teteracycline

131 (82.4%)

28 (17.6%)

Tobramycin

131 (82.4%)

28 (17.6%)

Tazobactam/Piperacillin

154 (96.9%)

5 (3.1%)

MacConkey media plates. Confirmation of ESBL production
was done using the combined disc method [ceftazidime
(CAZ 30μg) and cefotaxime (CTX 30μg) in combination
with clavulanate (CLA 10μg), Becton Dickinson, New Jersey,
USA] as per the Clinical Laboratory Standards Institute (CLSI
2009) guidelines on Mueller Hinton with 5% sheep blood
agar plates, and antibiotic susceptibility performed using
VITEK 2 (version 4.01, bioMerieux, Marcy-l’Etoile, France) and
interpreted using the same CLSI 2009 guidelines. Klebsiella
pneumoniae K6 ATCC 700603 (ESBL producer) and Escherichia
coli ATCC 25922 (non-ESBL producer) served as the positive
and negative controls respectively.
Eighteen antimicrobial agents were included; amoxicillin/
clavulanate, ampicillin, ceftazidime, cefuroxime, ciprofloxacin,

cefpodoxime, cefotaxime, gentamicin, imipenem, levofloxacin,
meropenem, nitrofurantoin, piperacillin, roxithromycin,
sulfamethoxazole/trimethoprime, teteracycline, tobramycin,
and tazobactam/piperacillin.
Data were analyzed using the statistical package for social
sciences (SPSS 15.0, IBM SPSS, New York, USA).
Contingency table analysis was done by a chi-square test
or two-tailed Fisher’s exact test where applicable. A p-value
of less than 0.05 was considered as statistically significant.
Ethical approval was granted by the Aga Khan University
Hospital Nairobi Ethics Committee.

Findings

Isolate characteristics

Out of the 336 isolates initially included, 177 isolates could not
either be revived, did not have patient details, were neither E.
coli nor K. pneumoniae on retesting with VITEK 2, or were not
ESBL producers and therefore excluded leaving 159 isolates.
A hundred and nine of the isolates (68.6%) were E. coli and
50 (31.4%) were K. pneumoniae. Outpatient specimens were 87
(45.3%) and inpatient 72 (45.3%). Escherichia coli were isolated
more frequently in outpatients than K. pneumoniae (p < 0.05).
Urine was the most common specimen processed with 115
(72%) of the samples. More than half of the urine samples
were from outpatients. Other specimens were fewer and
mostly from in-patients (Table 1). The ages of patients from
whom the specimens were recovered ranged from 2 days to
90 years with a median of 42 years.

Antibiotic susceptibility patterns

A large proportion of the isolates (> 80%) were resistant to all
classes of antibiotics tested apart from the carbapenems to
which resistance was found in a single isolate. The proportion
of isolates resistant to nitrofurantoin was substantially lower
at 23% and 63% for gentamicin (Table 2).
There were significant species specific differences in the
resistance patterns to some antibiotics. Klebsiella pneumoniae
had a higher proportion of isolates resistant to ceftazidime,
gentamicin and nitrofurantoin than E. coli isolates. In turn E. coli
had a higher proportion of isolates resistant to ciprofloxacin,
levofloxacin and tetracycline (Table 3).

Discussion

Our study analyzed 159 isolates from in-patients and outpatients, thus encompassing both hospital and community
acquired infections due to ESBL producing E. coli and K.
pneumoniae.
The two bacteria species studied had high proportions
of resistant isolates to most antimicrobial agents with the
exception of carbapenems and nitrofurantoin.
Similar findings have been reported in other studies in Iran
and Tanzania [9,10]. In these two studies imipenem was shown
to be the most active antibiotic against the ESBL producing
isolates and nitrofurantoin showed moderate activity.
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Table3. Significant species specific differences in antimicrobial
resistance.
Antibiotic
Ceftazidime
Ciprofloxacin
Levofloxacin
Nitrofurantoin
Tetracycline

Sensitivity E. coli (n=109) K. pneumoniae (n=50)
R

95

49

S

14

1

R

101

31

S

8

19

R

99

29

S

10

21

R

12

25

S

97

25

R

96

35

S

13

15

P-value
0.038
<0.001
<0.001
<0.001
0.005

R=resistant, S=sensitive

The finding that nitrofurantoin remains active in the majority
of isolates is clinically important to the outpatient setting,
where most of the isolates from urine tended to be E. coli or
K. pneumoniae.
Nitrofurantoin can therefore be used effectively for most
non-life threatening urinary tract infections with little regard
to the antibiotic resistance mechanisms at play among ESBL
producing isolates. From our experience many clinicians
prefer to prescribe other drugs yet nitrofurantoin remains
effective in most cases where there are multiple resistances
as is also evident in other studies [11,12].
Given the popularity of fluoroquinolones in treating a
variety of infections including respiratory, gastrointestinal and
urinary tract infections, the two drugs tested (ciprofloxacin
and levofloxacin) fared poorly with >80% of the isolates
showing resistance to both. This is not surprising among
ESBL producers and this phenomenon is well described in
the literature. The CTX-M genotype is the one that has most
been associated with this resistance [6,13].
The CTX-M genotype has been documented locally. A
previous study done in this University hospital using part
of the 159 isolates found the CTX-M genotype the most
predominant being present in 46 (88.5%) of the 52 ESBL
isolates tested [14]. It has also been suggested that the use
of fluoroquinolones selects for and results in the spread of
this genotype [15].
The resistance to carbapenems was low in our study and
the single isolate that displayed resistance to the two drugs
in this class needs further investigation to determine the
probable additional mechanism of resistance. While this class
of drugs remains useful for treating serious infections due to
multidrug resistant enteric bacteria in our set up, the single
isolate resistant to carbapenems is clinically relevant and
suggests that this pattern of resistance should be monitored
closely by microbiology laboratories.
The clinical utility of cephalosporins even with the evidence
of in vitro activity in isolates that are ESBL producers remain
controversial. The CLSI guidelines state they should be reported
as resistant, a position that is held by some researchers while
others suggest that there may be a limited clinical role for
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cephalosporins with activity against ESBL producers [16]. Our
data suggests that cephalosporins would be of limited use in
the treatment of ESBL related infections in our institution as the
proportion of resistant isolates was high. These observations
also apply to the β-lactam/β-lactam inhibitor combinations
for which we observed a high proportion of isolates with
MICs in the resistant range. A possible explanation for the
latter observation is the presence of additional resistance
mechanisms which as noted above may be acquired together
with ESBLs. However, these additional mechanisms were not
specifically looked for in this study.
The screening for ESBL production is not routinely done
in many clinical laboratories in this country and the impact
of treatment failure associated with these infections when
treated with cephalosporins is not well documented.

Conclusions

ESBL producing E. coli and K. pneumoniae display multiple
resistances to various classes of antimicrobials and are
therefore important to identify and treat accordingly. In
our study the carbapenems and nitrofurantoin retain good
activity and would thus be the drugs of choice for empiric
therapy in life threatening infections and non-complicated
urinary tract infections respectively. There is need to carry
out more studies to determine the epidemiology of ESBL
related infections and the associated clinical burden locally.
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